growth factor receptor


Also found in: Acronyms, Wikipedia.

growth factor receptor

a plasma membrane-spanning protein that binds with a specific growth factor on the external surface of a cell and transduces a signal that triggers cell division.
References in periodicals archive ?
The results indicate that the interactions between estrogen, progesterone and epidermal growth factor receptor pathways may be considered relevant targets for the treatment of hormone-dependent breast cancers," she said.
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
Scope - DelveInsight's report provides a Fibroblast Growth Factor Receptor 1 (FGFR1) Inhibitors Landscape across the globe - The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information - Coverage of the Fibroblast Growth Factor Receptor 1 (FGFR1) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Fibroblast Growth Factor Receptor 1 (FGFR1) Inhibitors and also provide company profiling - Pipeline products coverage based on various stages of development from NDA filings to discovery.
Epidermal Growth Factor Receptor (EGFR) inhibitors are currently used to treat non-small cell lung cancer, pancreatic, colorectal, and head & neck cancer.
Panitumumab is an investigational fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFr), a protein that plays an important role in cancer cell signaling.
ERBITUX is an IgG1 monoclonal antibody (IgG1 MAb) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1).
Amgen (NASDAQ:AMGN), the world's largest biotechnology company, today announced interim results from two Phase 2 studies of panitumumab, an investigational fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFr).
Preliminary results of the study suggest that the toxicity profile of IMC-1121B is distinct from other VEGF pathway inhibitors and that its pharmacokinetic profile is similar to other growth factor receptor pathway antibodies.
Five different breast tumor cell lines representing major subtypes and varied genetic backgrounds were tested, including p53 and ER (estrogen receptor) positive and negative lines, HER2 (epidermal growth factor receptor 2) positive cells, BRCA1 mutant cells and doxorubicin-resistant cells.
IMC-11F8, currently in Phase I testing in Europe, is a fully human, high-affinity antibody that blocks ligand-dependent activation of the epidermal growth factor receptor (EGFR).
Growth factor receptors, protein molecules produced by the gene HER-2/neu, cling to the surface of the tumor cells and wait for instructions to begin the cell division process.
Epidermal growth factor receptors are proteins that play an important role in cancer cell signaling.